Skip to main content
SpringerLink
Log in
Book cover

GHRH, GH, and IGF-I pp 241–256Cite as

Potential Benefits and Risks in Treating the Hyposomatomedinemia and Hypogonadism of Elderly Men

  • Conference paper

  • 86 Accesses

Part of the book series: Serono Symposia USA ((SERONOSYMP))

Abstract

When a deficiency of growth hormone (GH) or testosterone occurs in men during early or mid-adulthood, hormone replacement is an important consideration. Because of its favorable anabolic, hematopoietic, androgenic, and antiosteopenic effects, there is usually little question that testosterone should be prescribed. Treatment with human GH (hGH), a more expensive and only recently available medication, is now also being advocated by some endocrinologists because of its beneficial actions on body composition, work capacity, and quality of life (1-5).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Degerblad M, Almkvist O, Grunditz R, et al. Physical and psychological capabilities during substitution therapy with recombinant growth hormone in adults with growth hormone deficiency. Acta Endocrinol (Copenh) 1990; 123:185–93.

    CAS  Google Scholar 

  2. Jorgensen JOL, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989;1:1221–5.

    Article  PubMed  CAS  Google Scholar 

  3. Lamberts SWJ, Valk NK, Binnerts A. The use of growth hormone in adults: a changing scene. Clin Endocrinol 1992;37:111–5.

    Article  CAS  Google Scholar 

  4. Hager A. Should adults with growth hormone deficiency be maintained on growth hormone substitution therapy? Acta Paediatr Scand (Suppl) 1989; 362:72–5.

    Article  CAS  Google Scholar 

  5. Salomon F, Cuneo RC, Hesp R, et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989;321:1797–803.

    Article  PubMed  CAS  Google Scholar 

  6. Harman SM, Blackman MR. Growth hormone, IGF-I, gonadal steroids, and aging. Aging Clin Exp Res 1992;4:257–9.

    CAS  Google Scholar 

  7. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993;14:20–39.

    PubMed  CAS  Google Scholar 

  8. Abbasi AA, Drinka PJ, Mattson DE, et al. Low circulating levels of insulin-like growth factors and testosterone in chronically institutionalized elderly men. J Am Geriatr Soc 1993;41:975–82.

    PubMed  CAS  Google Scholar 

  9. Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab 1990;71: 963–9.

    Article  PubMed  CAS  Google Scholar 

  10. Rudman D. Growth hormone, body composition and aging. J Am Geriatr Soc 1985;33:800.

    PubMed  CAS  Google Scholar 

  11. Roubenoff R, Rall LC. Humoral mediation of changing body composition during aging and chronic inflammation. Nutr Rev 1993;51:1–11.

    Article  PubMed  CAS  Google Scholar 

  12. Kelijman M. Age related alterations of the growth hormone/insulin-like growth factor I axis. J Am Geriatr Soc 1991;39:295–307.

    PubMed  CAS  Google Scholar 

  13. Hartman ML, Faria ACS, Vance ML, et al. Temporal structure of in vivo growth hormone secretory events in humans. Am J Physiol 1991;260:E101–10.

    PubMed  CAS  Google Scholar 

  14. Southren AL, Gordon GG, Tochimoto S, et al. Mean plasma concentration, metabolic clearance and basal plasma production rates of testosterone in normal young men and women using a constant infusion procedure: effect of time of day and plasma concentration on the metabolic clearance rate of testosterone. J Clin Endocrinol Metab 1967;27:686–94.

    Article  PubMed  CAS  Google Scholar 

  15. Frasier SO, Lippe BM. Clinical review 11: the rational use of growth hormone during childhood. J Clin Endocrinol Metab 1990;71:269–73.

    Article  PubMed  CAS  Google Scholar 

  16. Aceto T, Frazier SD, Hayles AB, et al. Collaborative study of the effects of human growth hormone in growth hormone deficiency; I. First year of therapy. J Clin Endocrinol Metab 1972;35:483–96.

    Article  PubMed  Google Scholar 

  17. Wilson JD, Griffin JE. The use and misuse of androgens. Metabolism 1980;29:1278–95.

    Article  PubMed  CAS  Google Scholar 

  18. Cuneo RC, Salomon F, Wiles CM, et al. Growth hormone treatment in growth hormone-deficient adults; I. Effects on muscle mass and strength. J Appl Physiol 1991;70:688–94.

    PubMed  CAS  Google Scholar 

  19. Cuneo RC, Salomon F, Wiles CM, et al. Growth hormone treatment in growth hormone-deficient adults; II. Effects on exercise performance. J Appl Physiol 1991;70:695–700.

    PubMed  CAS  Google Scholar 

  20. Degerblad M, Elgindy N, Hall K, et al. Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocrinol (Copenh) 1992;126:387–93.

    CAS  Google Scholar 

  21. Christiansen JS, Jorgensen JO, Pedersen SA, et al. Effects of growth hormone on body composition in adults. Horm Res 1991;36:73–81.

    Article  Google Scholar 

  22. Rudman D, Feller AG, Nagraj HS, et al. Effect of human growth hormone in men over sixty years old. N Engl J Med 1990;323:1–6.

    Article  PubMed  CAS  Google Scholar 

  23. Snyder PJ. Clinical use of androgens. Annu Rev Med 1984;35:207–17.

    Article  PubMed  CAS  Google Scholar 

  24. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75:1092–8.

    Article  PubMed  CAS  Google Scholar 

  25. Crist DM, Peake GT, Egan PA, et al. Body composition response to exogenous GH during training in highly conditioned adults. J Appl Physiol 1988;65:579–84.

    PubMed  CAS  Google Scholar 

  26. Crist DM, Stackpole PJ, Peake GT. Effects of androgenic-anabolic steroids on neuromuscular power and body composition. J Appl Physiol 1983;54: 366–70.

    Article  PubMed  CAS  Google Scholar 

  27. Herndon DN, Barrow RE, Kunkel KR, et al. Effects of recombinant human growth hormone on donor-site healing in severely burned children. Ann Surg 1990;212:424–30.

    Article  PubMed  CAS  Google Scholar 

  28. Koskinen EVS, Lindholm RV, Nieminen RA, et al. Human growth hormone in delayed union and non-union of fractures. Int Orthop 1978;1: 317–22.

    Article  Google Scholar 

  29. Ward HC, Halliday D, Sim JW. Protein and energy metabolism with biosynthetic human growth hormone after gastrointestinal surgery. Ann Surg 1987;206:56–61.

    Article  PubMed  CAS  Google Scholar 

  30. Hall K, Sara VR. Somatomedin levels in childhood, adolescence and adult life. Clin Endocrinol Metab 1984;13:91–112.

    Article  PubMed  CAS  Google Scholar 

  31. Clemmons DR, Van Wyk JJ. Factors controlling blood concentration of somatomedin C. Clin Endocrinol Metab 1984;13:113–43.

    Article  PubMed  CAS  Google Scholar 

  32. Furlanetto RW, Underwood LE, Van Wyk JJ, et al. Estimation of somatomedin C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest 1977;60:648–57.

    Article  CAS  Google Scholar 

  33. Daughaday WH, Mariz IK, Blethen SL. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acidethanol-extracted serum. J Clin Endocrinol Metab 1980;51:781–8.

    Article  PubMed  CAS  Google Scholar 

  34. Zadik Z, Chalew SA, McCarter RJ Jr, et al. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 1985;60:513–6.

    Article  PubMed  CAS  Google Scholar 

  35. Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in men: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987;64:51–8.

    Article  PubMed  CAS  Google Scholar 

  36. Jorgensen JOL, Moller N, Lauritzen T, et al. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab 1990;70:207–14.

    Article  PubMed  CAS  Google Scholar 

  37. Rudman D, Friedes D, Patterson JH, et al. Diurnal variation in the responsiveness of human subjects to human growth hormone. J Clin Invest 1973;52:912–8.

    Article  PubMed  CAS  Google Scholar 

  38. Jorgensen JO. Human growth hormone replacement therapy: pharmacological and clinical aspects. Endocr Rev 1991;12:189–207.

    Article  PubMed  CAS  Google Scholar 

  39. Findlay JC, Place V, Snyder PJ. Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab 1989;68:369–73.

    Article  PubMed  CAS  Google Scholar 

  40. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinal Metab 1980;51:1335–9.

    Article  CAS  Google Scholar 

  41. Cohn L, Feller AG, Draper MW, et al. Carpal tunnel syndrome and gynecomastia during growth hormone treatment in elderly men with low circulating IGF-I concentrations. Clin Endocrinol 1993;139:417–25.

    Article  Google Scholar 

  42. Kaiser FE, Silver AJ, Morley JE. The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc 1991;39:235–40.

    PubMed  CAS  Google Scholar 

  43. Pape GS, Friedman M, Underwood LE, et al. The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest 1991;99:1495–500.

    Article  PubMed  CAS  Google Scholar 

  44. Binnerts A, Wilson JH, Lamberts SW. The effects of human growth hormone administration in elderly adults with recent weight loss. J Clin Endocrinol Metab 1988;67:1312–6.

    Article  PubMed  CAS  Google Scholar 

  45. Clemmons DR, Snyder DK, Williams R, et al. Growth hormone administration conserves lean body mass during dietary restriction in obese subjects. J Clin Endocrinol Metab 1987;64:878–82.

    Article  PubMed  CAS  Google Scholar 

  46. Jiang ZM, He GZ, Zhang SY, et al. Low dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation. Ann Surg 1989;210:513–25.

    Article  PubMed  CAS  Google Scholar 

  47. Manson JM, Wilmore DW. Positive nitrogen balance with human growth hormone and hypocaloric intravenous feeding. Surgery 1986;100:188–97.

    PubMed  CAS  Google Scholar 

  48. Herndon DN, Barrow RE, Kunkel KR, et al. Effects of recombinant human growth hormone on donor-site healing in severely burned children. Ann Surg 1990;212:424–31.

    Article  PubMed  CAS  Google Scholar 

  49. Horber FF, Haymond MW. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990;86:265–72.

    Article  PubMed  CAS  Google Scholar 

  50. Morley JE, Perry NM 3rd, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993;41:149–52.

    PubMed  CAS  Google Scholar 

  51. Jackson JA, Waxman J, Spiekerman AM. Prostatic complications of testosterone replacement therapy. Arch Intern Med 1989;149:2365–6.

    Article  PubMed  CAS  Google Scholar 

  52. Kraus DJ, Taub HA, Lantiga LJ, et al. Risks of blood volume changes in hypogonadal men treated with testosterone enenthate for erectile impotence. J Urol 1991;146:1566–70.

    Google Scholar 

  53. Uzych L. Anabolic-androgenic steroids and psychiatric related effects: a review. Can J Psychiatry 1992;37:23–8.

    PubMed  CAS  Google Scholar 

  54. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987;8:1–28.

    Article  PubMed  CAS  Google Scholar 

  55. Matsumoto AM, Sandblom RE, Schoene RB, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol 1985;22:713–21.

    Article  CAS  Google Scholar 

  56. Daughaday WH. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 1990;127:1–4.

    Article  PubMed  CAS  Google Scholar 

  57. Macauly VM, Teale JD, Everard MJ, et al. Somatomedin-C/insulin-like growth factor-I is a mitogen for human small cell lung cancer. Br J Cancer 1988;57:91–3.

    Article  PubMed  CAS  Google Scholar 

  58. Cullen KJ, Yee D, Sly WS, et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 1990;50:48–53.

    PubMed  CAS  Google Scholar 

  59. Jammes H, Peyrat JP, Ban E, et al. Insulin-like growth factor 1 receptors in human breast tumor: localisation and quantification by histo-autoradiographic analysis. Br J Cancer 1992;66:248–53.

    Article  PubMed  CAS  Google Scholar 

  60. Osborne CK, Clemmons DR, Arteaga CL. Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem 1990;37:805–9.

    Article  CAS  Google Scholar 

  61. Ezzat S, Melmed S. Clinical review 18: are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 1991;72:245–9.

    Article  PubMed  CAS  Google Scholar 

  62. Brunner JE, Johnson CC, Zafar S, et al. Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clin Endocrinol 1990;32:65–71.

    Article  CAS  Google Scholar 

  63. Bengtsson BA, Eden S, Ernest I, et al. Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988;223:327–35.

    Article  PubMed  CAS  Google Scholar 

  64. Henderson BE, Ross RK, Pike MC, et al. Endogenous hormones as a major factor in human cancer. Cancer Res 1982;42:3232–9.

    PubMed  CAS  Google Scholar 

  65. Bluestone R, Bywaters EG, Hartog M, et al. Acromegalic arthropathy. Ann Rheum Dis 1971;30:243–58.

    Article  PubMed  CAS  Google Scholar 

  66. Detenbeck LC, Tressler HA, O’Duffy JD, et al. Peripheral joint manifestations of acromegaly. Clin Orthop 1973;91:119–27.

    Article  PubMed  Google Scholar 

  67. Jadresic A, Banks LM, Child DF, et al. The acromegaly syndrome: relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. Q J Med 1982;51:189–204.

    PubMed  CAS  Google Scholar 

  68. Nabarro JDN. Acromegaly. Clin Endocrinol (Oxf) 1987;26:481–512.

    Article  CAS  Google Scholar 

  69. Van der Werff ten Bosch JJ, Bot A. Growth hormone and androgen effects in the third decade. Acta Endocrinol Suppl 1986;279:29–34.

    Google Scholar 

  70. Zachmann M, Prader A. Anabolic and androgenic effect of testosterone in sexually immature boys and its dependency on growth hormone. J Clin Endocrinol Metab 1970;30:85–95.

    Article  PubMed  CAS  Google Scholar 

  71. Pertzelan A, Blum I, Grunebaum M, et al. The combined effect of growth hormone and methandrostenolone on the linear growth of patients with multiple pituitary hormone deficiencies,. Clin Endocrinol 1977;6:271–6.

    Article  CAS  Google Scholar 

  72. MacGillivray MH, Kolotkin M, Munschauer RW. Enhanced linear growth responses in hypopituitary dwarfs treated with growth hormone plus androgen versus growth hormone alone. Pediatr Res 1974;8:103–8.

    Article  PubMed  CAS  Google Scholar 

  73. Ullea-Qguirre A, Blizzard RM, Garcia-Rubi E, et al. Testosterone and oxandrolone, a nonaromatizable androgen, specifically amplify the mass and rate of growth hormone (GH) secreted per burst without altering GH secretory burst duration or frequency or the GH half-life. J Clin Endocrinol Metab 1990;71:846–54.

    Article  Google Scholar 

  74. Belgorosky A, Martinez A, Domene H, et al. High serum sex hormone-binding globulin (SHBG) and low serum non-SHBG-bound testosterone in boys with idiopathic hypopituitarism: effect of recombinant human growth hormone treatment. J Clin Endocrinol Metab 1987;65:107.

    Google Scholar 

  75. Corpas E, Harman SM, Pineyro MA, et al. Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1–44 for 14 days increase GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1993;76:134–8.

    Article  PubMed  CAS  Google Scholar 

  76. Corpas E, Harman SM, Pineyro MA, et al. Growth hormone (GH)-releasing hormone-(1–29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992;75: 530–5.

    Article  PubMed  CAS  Google Scholar 

  77. Chawla RK, Parks JS, Rudman D. Structural variants of human growth hormone: biochemical, genetic, and clinical aspects. Annu Rev Med 1983; 34:519–47.

    Article  PubMed  CAS  Google Scholar 

  78. Muller EE. Clinical implications of growth hormone feedback mechanisms. Horm Res 1990;33(suppl):90–6.

    PubMed  Google Scholar 

  79. Clemmons DR. Editorial: role of insulin-like growth factor-I in reversing catabolism. J Clin Endocrinol Metab 1992;75:1183–5.

    Article  PubMed  CAS  Google Scholar 

  80. Leroith D, Clemmons D, Nissley P, et al. Insulin-like growth factors in health and disease. Ann Intern Med 1992;116:854–62.

    PubMed  CAS  Google Scholar 

  81. DeVol DL, Rotwein P, Sadow JL, et al. Activation of insulin-like growth factor gene expression during work induced skeletal muscle growth. Am J Physiol 1990;259:E89–95.

    PubMed  CAS  Google Scholar 

  82. Behringer RR, Lewin TM, Quaife CJ, et al. Expression of insulin-like growth factor-I stimulates normal somatic growth in growth hormone-deficient transgenic mice. Endocrinology 1990;127:1033–40.

    Article  PubMed  CAS  Google Scholar 

  83. Clemmons DR. Role of insulin-like growth factor-1 in reversing catabolism. J Clin Endocrinol Metab 1992;75:1183–5.

    Article  PubMed  CAS  Google Scholar 

  84. Laron Z, Anin S, Klipper-Aurbach YK, et al. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992;339:1258–61.

    Article  PubMed  CAS  Google Scholar 

  85. Clemmons DR, Smith-Banks A, Underwood LE. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J Clin Endocrinol Metab 1992;75:234–8.

    Article  PubMed  CAS  Google Scholar 

  86. Guler HP, Zapf J, Scheiwiller E, et al. Recombinant human insulin-like growth factor-I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci USA 1988;85:4889–93.

    Article  PubMed  CAS  Google Scholar 

  87. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor-I in healthy adults. N Engl J Med 1987;317: 137–40.

    Article  PubMed  CAS  Google Scholar 

  88. Jacob R, Barrett E, Plewe G, et al. Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat: comparison with insulin. J Clin Invest 1989;83:1717–23.

    Article  PubMed  CAS  Google Scholar 

  89. Guler HP, Schmid C, Zapf J, et al. Effects of recombinant insulin-like growth factor-I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 1989;86:2868–72.

    Article  PubMed  CAS  Google Scholar 

  90. Boulware SD, Tamborlane WV, Sherwin RS, et al. Diverse effects of insulin-like growth factor-I on glucose, lipid and amino acid metabolism. Am J Physiol 1992;262:E130–3.

    PubMed  CAS  Google Scholar 

  91. Bennett AE, Wahner HW, Riggs BL, et al. Insulin-like growth factors I and II: aging and bone density in women. J Clin Endocrinol Metab 1984;59:7014.

    Article  Google Scholar 

  92. Gray A, Feldman HA, McKinlay JB, et al. Age, disease and changing sex hormone levels in middle aged men: results of the Massachusetts male aging study. J Clin Endocrinol Metab 1991;73:1016–25.

    Article  PubMed  CAS  Google Scholar 

  93. Yamaji T, Ibayashi H. Plasma dehydroepiandrosterone sulfate in normal and pathological conditions. J Clin Endocrinol Metab 1969;29:273–8.

    Article  PubMed  CAS  Google Scholar 

  94. Smith MR, Rudd BT, Shirley A, et al. A radioimmunoassay for the estimation of serum dehydroepiandrosterone sulphate in normal and pathological sera. Clin Chim Acta 1975;65:5–13.

    Article  PubMed  CAS  Google Scholar 

  95. Orentreich N, Brind JL, Rizer RL, et al. Age changes and sex differences in serum dehyroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984;59:551–5.

    Article  PubMed  CAS  Google Scholar 

  96. Nordin BE, Robertson A, Seamark RF, et al. The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women. J Clin Endocrinol Metab 1985;60:651–7.

    Article  PubMed  CAS  Google Scholar 

  97. Deutsch S, Benjamin F, Seltzer V, et al. The correlation of serum estrogens and androgens with bone density in the late postmenopause. Int J Gynaecol Obstet 1987;25:217–22.

    Article  PubMed  CAS  Google Scholar 

  98. Devogelaer JP, Crabbe J, Nagant de Deuxchaisnes C. Bone mineral density in Addison’s disease: evidence for an effect of adrenal androgens on bone mass. Br Med J 1987;294:798–800.

    Article  CAS  Google Scholar 

  99. Wild RA, Buchanan JR, Myers C, et al. Declining adrenal androgens: an association with bone loss in aging women. Proc Soc Exp Biol Med 1987; 186:355–60.

    PubMed  CAS  Google Scholar 

  100. Taelman P, Kaufman JM, Janssens X, et al. Persistence of increased bone resorption and possible role of dehydroepiandrosterone as a bone metabolism determinant in osteoporotic women in late post menopause. Maturitas 1989;11:65–73.

    Article  PubMed  CAS  Google Scholar 

  101. Yen TT, Allan JA, Pearson DV, et al. Prevention of obesity in Avy/a mice by dehydroepiandrosterone. Lipids 1977;12:409–13.

    Article  PubMed  CAS  Google Scholar 

  102. Cleary MP, Shepherd A, Jenks B. Effect of dehydroepiandrosterone on growth in lean and obese Zucker rats. J Nutr 1984;114:1242–51.

    PubMed  CAS  Google Scholar 

  103. Nestler JE, Barlascini CO, Clore NJ, et al. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988;66:57–61.

    Article  PubMed  CAS  Google Scholar 

  104. Ettinger B, Genant HK, Cann CE. Long term estrogen replacement therapy prevents bone loss and fracture. Ann Intern Med 1985;102:319–24.

    PubMed  CAS  Google Scholar 

  105. Ettinger B, Genant HK, Cann CE. Post menopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 1987; 106:40–5.

    PubMed  CAS  Google Scholar 

  106. Aloia JF, Vaswani A, Kapoor A, et al. Treatment of osteoporosis with calcitonin, with and without growth hormone. Metab Clin Exp 1985;34: 124–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Daniel Rudman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kaup R. Shetty
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology and Metabolism Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA

    Marc R. Blackman M.D.

  2. Division of Geriatric Medicine and Gerontology Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA

    Jesse Roth M.D.  & Jay R. Shapiro M.D.  & 

  3. Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA

    S. Mitchell Harman M.D., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer Science+Business Media New York

About this paper

Cite this paper

Rudman, D., Shetty, K.R. (1995). Potential Benefits and Risks in Treating the Hyposomatomedinemia and Hypogonadism of Elderly Men. In: Blackman, M.R., Roth, J., Harman, S.M., Shapiro, J.R. (eds) GHRH, GH, and IGF-I. Serono Symposia USA. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-0807-5_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-0807-5_23

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-6908-3

  • Online ISBN: 978-1-4612-0807-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation